Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry

• DOI: 10.1016/j.atherosclerosis.2023.03.013
• Publication Date: 2023-03-30T08:34:07Z
• Authors: Annette M.H. Gale...; Janneke W.C.M. Mu...; Kim Steward; Jeanine E. Roeter...
• Keywords: PCSK9

Proprotein convertase subtilisin/kexin 9 monoclonal antibodies (PCSK9 mAbs) reduce low-density lipoprotein (LDL-c) with a favourable safety profile. Available data from PCSK9 antibody trials suggest LDL-c reduction is lower in women compared to men. Data real-world setting scarce. The aim of this study was assess sex differences efficacy and clinical care.All patients starting evolocumab or alirocumab our lipid clinic were included prospective registry. We collected information, including baseline follow-up mean LDL-C levels after initiation mAbs treatment. In addition, side effects discontinuation recorded.We analysed 436 (209 women), age 58 ± 11 years. Women had higher men (4.7 1.6 mmol/L vs 4.1 1.4 mmol/L, p < 0.01). resulted less relative (50% 61% p<0.01), but equal absolute (respectively 2.3 1.3 2.5 1.1 = 0.087). often reached target than 72%). No observed reporting (women 32% 27% 0.26) 13% 10%, 0.46).In practice, are effective reducing equally safe, implying the importance metabolism.